Drug Details
| General Information of the Drug (ID: DR2080) | ||||
|---|---|---|---|---|
| Name |
Topotecan
|
|||
| Synonyms |
Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Ovarian cancer [ICD-11: 2C73] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C23H23N3O5
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
|
|||
| InChI |
1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
|
|||
| InChIKey |
UCFGDBYHRUNTLO-QHCPKHFHSA-N
|
|||
| CAS Number |
CAS 123948-87-8
|
|||
| GDSC | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Daidzein | Glycine max | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCG2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| In-vivo Model | Adult female athymic nude mice (six-week-old) were injected with MCF7 cells (5*106 cells/mouse) to construct subcutaneous breast cancer xenografts. | |||||
| Experimental
Result(s) |
Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. | |||||
| Genistein | Glycine max | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Genistein-topotecan combination was significantly more efficacious in reducing LNCaP cell viability compared with either genistein or topotecan alone. | |||||
| Thymoquinone | Nigella sativa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Thymoquinone, when combined with topotecan in noncytotoxic doses, produced synergistic antiproliferative and proapoptotic effects in AML cells. | |||||
| Vincristine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Rh18 | CVCL_1659 | Alveolar rhabdomyosarcoma | Homo sapiens | ||
| D283 Med | CVCL_1155 | Medulloblastoma | Homo sapiens | |||
| Daoy | CVCL_1167 | Medulloblastoma | Homo sapiens | |||
| SJ-GBM2 | CVCL_M141 | Glioblastoma | Homo sapiens | |||
| NB-EB | Neuroblastoma | Homo sapiens | ||||
| RMSs | Embryonal rhabdomyosarcoma | Homo sapiens | ||||
| Experimental
Result(s) |
The therapeutic effect of combining topotecan with vincristine was greater than additive in most tumor models of childhood solid tumors tested. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Molecule Info | [6] | |
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | DNA replication | Click to Show/Hide | ||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | Click to Show/Hide | ||
| WikiPathways | Integrated Pancreatic Cancer Pathway | Click to Show/Hide | ||
